OBJECTIVE: To determine the impact of cognitive behavioral therapy on outcomes in primary care, office-based buprenorphine/naloxonetreatment of opioid dependence. METHODS: We conducted a 24-week randomized clinical trial in 141 opioid-dependent patients in a primary care clinic. Patients were randomized to physician management or physician management plus cognitive behavioral therapy. Physician management was brief, manual guided, and medically focused; cognitive behavioral therapy was manual guided and provided for the first 12 weeks of treatment. The primary outcome measures were self-reported frequency of illicit opioid use and the maximum number of consecutive weeks of abstinence from illicit opioids, as documented by urine toxicology and self-report. RESULTS: The 2 treatments had similar effectiveness with respect to reduction in the mean self-reported frequency of opioid use, from 5.3 days per week (95% confidence interval, 5.1-5.5) at baseline to 0.4 (95% confidence interval, 0.1-0.6) for the second half of maintenance (P<.001 for the comparisons of induction and maintenance with baseline), with no differences between the 2 groups (P=.96) or between the treatments over time (P=.44). For the maximum consecutive weeks of opioid abstinence there was a significant main effect of time (P<.001), but the interaction (P=.11) and main effect of group (P=.84) were not significant. No differences were observed on the basis of treatment assignment with respect to cocaine use or study completion. CONCLUSIONS: Among patients receiving buprenorphine/naloxone in primary care for opioid dependence, the effectiveness of physician management did not differ significantly from that of physician management plus cognitive behavioral therapy.
RCT Entities:
OBJECTIVE: To determine the impact of cognitive behavioral therapy on outcomes in primary care, office-based buprenorphine/naloxone treatment of opioid dependence. METHODS: We conducted a 24-week randomized clinical trial in 141 opioid-dependent patients in a primary care clinic. Patients were randomized to physician management or physician management plus cognitive behavioral therapy. Physician management was brief, manual guided, and medically focused; cognitive behavioral therapy was manual guided and provided for the first 12 weeks of treatment. The primary outcome measures were self-reported frequency of illicit opioid use and the maximum number of consecutive weeks of abstinence from illicit opioids, as documented by urine toxicology and self-report. RESULTS: The 2 treatments had similar effectiveness with respect to reduction in the mean self-reported frequency of opioid use, from 5.3 days per week (95% confidence interval, 5.1-5.5) at baseline to 0.4 (95% confidence interval, 0.1-0.6) for the second half of maintenance (P<.001 for the comparisons of induction and maintenance with baseline), with no differences between the 2 groups (P=.96) or between the treatments over time (P=.44). For the maximum consecutive weeks of opioid abstinence there was a significant main effect of time (P<.001), but the interaction (P=.11) and main effect of group (P=.84) were not significant. No differences were observed on the basis of treatment assignment with respect to cocaine use or study completion. CONCLUSIONS: Among patients receiving buprenorphine/naloxone in primary care for opioid dependence, the effectiveness of physician management did not differ significantly from that of physician management plus cognitive behavioral therapy.
Authors: P Crits-Christoph; L Siqueland; J Blaine; A Frank; L Luborsky; L S Onken; L R Muenz; M E Thase; R D Weiss; D R Gastfriend; G E Woody; J P Barber; S F Butler; D Daley; I Salloum; S Bishop; L M Najavits; J Lis; D Mercer; M L Griffin; K Moras; A T Beck Journal: Arch Gen Psychiatry Date: 1999-06
Authors: David A Fiellin; Michael V Pantalon; Juliana P Pakes; Patrick G O'Connor; Marek Chawarski; Richard S Schottenfeld Journal: Am J Drug Alcohol Abuse Date: 2002 Impact factor: 3.829
Authors: W Ling; C Charuvastra; J F Collins; S Batki; L S Brown; P Kintaudi; D R Wesson; L McNicholas; D J Tusel; U Malkerneker; J A Renner; E Santos; P Casadonte; C Fye; S Stine; R I Wang; D Segal Journal: Addiction Date: 1998-04 Impact factor: 6.526
Authors: Ivan D Montoya; David A Gorelick; Kenzie L Preston; Jennifer R Schroeder; Annie Umbricht; Lawrence J Cheskin; W Robert Lange; Carlo Contoreggi; Rolley E Johnson; Paul J Fudala Journal: Clin Pharmacol Ther Date: 2004-01 Impact factor: 6.875
Authors: Declan T Barry; Mark Beitel; Christopher J Cutter; David A Fiellin; Robert D Kerns; Brent A Moore; Lindsay Oberleitner; Lynn M Madden; Christopher Liong; Joel Ginn; Richard S Schottenfeld Journal: Drug Alcohol Depend Date: 2018-11-13 Impact factor: 4.492
Authors: Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Michael V Pantalon; Susan H Busch; Patricia H Owens; Kathryn Hawk; Steven L Bernstein; David A Fiellin Journal: J Gen Intern Med Date: 2017-02-13 Impact factor: 5.128
Authors: Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin Journal: JAMA Date: 2015-04-28 Impact factor: 56.272
Authors: Andrea Meier; Chantal Lambert-Harris; Mark P McGovern; Haiyi Xie; Melissa An; Bethany McLeman Journal: Am J Drug Alcohol Abuse Date: 2014-05-08 Impact factor: 3.829